Ten years of highly active antiretroviral therapy for HIV infection

被引:67
作者
Chen, Luke F.
Hoy, Jennifer
Lewin, Sharon R. [1 ]
机构
[1] Alfred Hosp, Infect Dis Unit, Melbourne, Vic, Australia
[2] Monash Univ, Dept Med, Melbourne, Vic 3004, Australia
[3] Alfred Hosp, Clin Res Unit, Melbourne, Vic, Australia
关键词
D O I
10.5694/j.1326-5377.2007.tb00839.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Over the past 10 years, the management of HIV infection has been transformed by an increased number of effective antiretrovirals (ARVs), with more convenient dosing and improved tolerability. Optimal management of HIV infection includes at least three effective ARVs; from at least two different drug classes. Current strategies and drugs can effectively control HIV and significantly reduce morbidity and mortality. However, no cure is yet possible. Appropriate use of ARVs leads to suppression of virological replication (to below the limit of detection using commercial assays to measure HIV in plasma) and an increase in CD4(+) T cells with few adverse effects. Greater than 95% adherence to drug therapy is required for effective viral suppression and immunological improvement. Monotherapy, two-drug combinations, sequential ARVs, drug "cycling", and treatment interruptions are ineffective management strategies and lead to earlier disease progression and emergence of drug resistance. Drug-drug interactions are common and caution is required when prescribing ARVs that inhibit or induce the cytochrome P450 pathway.
引用
收藏
页码:146 / 151
页数:6
相关论文
共 58 条
[31]   Antiretroviral-drug resistance among patients recently infected with HIV [J].
Little, SJ ;
Holte, S ;
Routy, JP ;
Daar, ES ;
Markowitz, M ;
Collier, AC ;
Koup, RA ;
Mellors, JW ;
Connick, E ;
Conway, B ;
Kilby, M ;
Wang, L ;
Whitcomb, JM ;
Hellmann, NS ;
Richman, DD .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :385-394
[32]   Assessing the effect of HAART on change in quality of life among HIV-infected women [J].
Liu C. ;
Weber K. ;
Robison E. ;
Hu Z. ;
Jacobson L.P. ;
Gange S.J. .
AIDS Research and Therapy, 3 (1)
[33]   Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir [J].
Mallal, S ;
Nolan, D ;
Witt, C ;
Masel, G ;
Martin, AM ;
Moore, C ;
Sayer, D ;
Castley, A ;
Mamotte, C ;
Maxwell, D ;
James, I ;
Christiansen, FT .
LANCET, 2002, 359 (9308) :727-732
[34]   The consistency of adherence to antiretroviral therapy predicts biologic outcomes for human immunodeficiency virus-infected persons in clinical trials [J].
Mannheimer, S ;
Friedland, G ;
Matts, J ;
Child, C ;
Chesney, M .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (08) :1115-1121
[35]   Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study [J].
Martin, A ;
Smith, DE ;
Carr, A ;
Ringland, C ;
Amin, J ;
Emery, S ;
Hoy, J ;
Workman, C ;
Doong, N ;
Freund, J ;
Cooper, DA .
AIDS, 2004, 18 (07) :1029-1036
[36]   Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant [J].
Martin, AM ;
Nolan, D ;
Gaudieri, S ;
Almeida, CA ;
Nolan, R ;
James, I ;
Carvalho, F ;
Phillips, E ;
Christiansen, FT ;
Purcell, AW ;
McCluskey, J ;
Mallal, S .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (12) :4180-4185
[37]   Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors:: a prospective cohort study [J].
Martinez, E ;
Mocroft, A ;
García-Viejo, MA ;
Pérez-Cuevas, JB ;
Blanco, JL ;
Mallolas, J ;
Bianchi, L ;
Conget, I ;
Blanch, J ;
Phillips, A ;
Gatell, JM .
LANCET, 2001, 357 (9256) :592-598
[38]   Characteristics of drug resistant HBV in an international collaborative study of HIV-HBV-infected individuals on extended lamivudine therapy [J].
Matthews, GV ;
Bartholomeusz, A ;
Locarnini, S ;
Ayres, A ;
Sasaduesz, J ;
Seaberg, E ;
Cooper, DA ;
Lewin, S ;
Dore, GJ ;
Thio, CL .
AIDS, 2006, 20 (06) :863-870
[39]   Cost effectiveness of combination HIV therapy - 3 years later [J].
Moore, RD .
PHARMACOECONOMICS, 2000, 17 (04) :325-330
[40]   Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease [J].
Murphy, EL ;
Collier, AC ;
Kalish, LA ;
Assmann, SF ;
Para, MF ;
Flanigan, TP ;
Kumar, PN ;
Mintz, L ;
Wallach, FR ;
Nemo, GJ .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (01) :17-26